Joseph Reginald Osborne
Affiliations: | 2001 | Columbia University, New York, NY |
Google:
"Joseph Osborne"Mean distance: 13.79 (cluster 11) | S | N | B | C | P |
Parents
Sign in to add mentor| Richard Axel | grad student | 2001 | Columbia | |
| (Genetic analysis of the establishment and maintenance of the olfactory topographic map.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ivanidze J, Skafida M, Pandya S, et al. (2020) Molecular Imaging of Striatal Dopaminergic Neuronal Loss and the Neurovascular Unit in Parkinson Disease. Frontiers in Neuroscience. 14: 528809 |
| Batra JS, Niaz MJ, Whang YE, et al. (2020) Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer. Urologic Oncology |
| Niaz MJ, Batra JS, Walsh RD, et al. (2020) Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 ( Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. The Oncologist |
| Vlachostergios PJ, Goswami S, Niaz MJ, et al. (2020) Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 45-45 |
| Tagawa ST, Osborne J, Niaz MJ, et al. (2020) Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 114-114 |
| Tagawa ST, Osborne J, Fernandez E, et al. (2020) Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 5560-5560 |
| Tagawa ST, Osborne J, Thomas C, et al. (2020) Abstract CT122: Phase I dose-escalation study of prostate-specific membrane antigen (PSMA)-targeted alpha emitter225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC) Tumor Biology |
| Sun M, Niaz M, Thomas C, et al. (2020) Abstract 6511: Androgen receptor (AR) genomic alterations and clinical outcome with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy Cancer Research. 80: 6511-6511 |
| Niaz MJ, Skafida M, Osborne J, et al. (2020) Pd16-11 Comparison Of Prostate-Specific Membrane Antigen (Psma)-Targeted Radionuclide Therapy (Trt) With Lutetium-177 (177Lu) Via Antibody J591 Vs Small Molecule Ligand Psma-617 The Journal of Urology. 203 |
| Ivanidze J, Roytman M, Sasson A, et al. (2019) Molecular imaging and therapy of somatostatin receptor positive tumors. Clinical Imaging. 56: 146-154 |